Sollpura represents the potentially first soluble, stable and non-pig derived pancreatic enzyme replacement therapy (PERT) to offer a novel solution to patients, especially young children and adults who are either unable to swallow multiple pills or are forced to use gastric tubes in order to maintain appropriate nutritional health. Unlike other enzyme products for the treatment of exocrine pancreatic insufficiency (EPI), Sollpura’s chemical characteristics, its solubility and stability, make it an ideal product in either a capsule or sachet formulation which can be conveniently co-administered with a variety of food products.

Sollpura provides numerous advantages over current approved PERTs:

Current PERTS are Suboptimal
Solpura represents an optimized PERT


Anthera is conducting two studies with Sollpura.

RESULT Study: The purpose of the RESULT study is to evaluate the non-inferiority of Sollpura compared to approved, porcine-derived, enterically-coated pancreatic enzyme replacement therapy when administered to patients with cystic fibrosis and endocrine pancreatic insufficiency. Learn more.

Simplicity Study: The SIMPLICITY study will evaluate the safety and efficacy of Sollpura powder for oral solution, supplied in sachets. Learn more.

Print Friendly